Interesting Case Series. Periorbital Richter Syndrome

Similar documents
Many people with non-hodgkin lymphoma have found an educational support group helpful. Support

Malignant Lymphomas and Plasma Cell Myeloma

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

Corporate Medical Policy

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on

Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)

Waldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May Morie Gertz MD, MACP

Treatment of low-grade non-hodgkin lymphoma

What is a Stem Cell Transplantation?

Lymphoma in Dogs: Diagnosis & Treatment

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Lymphomas after organ transplantation

Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

MEDICAL COVERAGE POLICY

Mantle Cell Lymphoma Understanding Your Treatment Options

Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology

LYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis

Cutaneous Lymphoma FAST FACTS

Leukemias and Lymphomas: A primer

CHRONIC LYMPHOCYTIC LEUKEMIA

Lymphoma Diagnosis and Classification

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA

Lymphoma Overview Joseph Leach, MD

Non-Hodgkin s lymphomas (NHLs) are a

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

The Treatment of Leukemia

Pediatric Oncology for Otolaryngologists

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN

Stem Cell Transplantation

Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Your NHL Journey. RITUXAN for Follicular Lymphoma and Diffuse Large B-cell Lymphoma (DLBCL) Indications. Important Safety Information

Non-Hodgkin Lymphoma Richard Orlowski, MD

Why discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time

SMALL CELL LUNG CANCER

Leukaemia and lymphoma what s the difference?

Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data

Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2

Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.

AA Life Insurance providing access to Best Doctors. AA Life Insurance is provided by Friends Life and Pensions Limited

Canine Lymphoma Frequently Asked Questions by Pet Owners

Mercy Health Fairfield Hospital Annual Report on 2010 Activities Non-Hodgkin Lymphoma Outcomes Study

Asymptomatic or smoldering myeloma with no symptoms and slow growing cancer cells

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:

Things You Don t Want to Miss in Multiple Myeloma

A Rare Image. Dean M. Cestari, MD Fred Jakobiec, MD Fred Hochberg, MD Joseph F. Rizzo III, MD Rebecca C. Stacy, MD PhD

Acute myeloid leukaemia (AML) in children

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015

Supplementary appendix

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION

Report series: General cancer information

Childhood Cancer in the Primary Care Setting

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Outline of thesis and future perspectives.

Guidelines for the Management of Follicular Lymphoma

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma

AA Life Insurance providing access to Best Doctors. AA Life Insurance is provided by Friends Life Limited

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

A Clinical Primer. for Managed Care Stakeholders

ACUTE MYELOID LEUKEMIA (AML),

Blood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)

Bone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital

FastTest. You ve read the book now test yourself

PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec)

Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.

Multiple Myeloma Patient s Booklet

Access to over 53,000 of the world s leading medical experts, from your first day of cover.

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

Does chronic lymphocytic leukemia increase the risk of osteoporosis?

Prior Authorization Guideline

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma

Non Hodgkin Lymphoma:

Non-Hodgkin s Lymphoma

A Framework of Competences for the Level 3 Training Special Study Module in Paediatric Oncology

HIV Case Conference: HIV Associated Lymphoma

SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Myeloma pathways to diagnosis UCLP audit

I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several

Acute Myeloid Leukemia

Transcription:

Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom; and b Division of Plastic Surgery, Royal Free Hospital, London, United Kingdom Correspondence: email m.gorman@me.com Keywords: Richter syndrome, CLL, eyelid, necrotizing fasciitis, diagnosis Figure 1. Richter syndrome affecting eyelids on the left side in our patient. Figure 2. Necrotizing fasciitis affecting both eyes.

DESCRIPTION A 70-year-old with a background of chronic lymphocytic leukemia (CLL) and progressive necrotic cutaneous periorbital lesions was incorrectly managed as having necrotizing fasciitis (NF) when referred to plastic surgery. The underlying pathological process of Richter syndrome was missed until it was too late for this patient. Richter syndrome is a transformation of CLL into higher-grade lymphomas, driven by viral infections, whose successful treatment is dependent on rapid diagnosis and aggressive targeted chemotherapy/immunomodulation. It more commonly presents with lymphadenopathy but may, as in this case, present as a necrotic cutaneous basin, being easily mistaken for other differential diagnosis.

QUESTIONS 1. What is Richter syndrome? 2. How is Richter syndrome diagnosed? 3. How do you distinguishing between necrotic cutaneous differential diagnoses in patients with CLL? 4. How should Richter syndrome be managed with cutaneous presentations?

DISCUSSION Richter syndrome is the transformation of CLL into diffuse, large B-cell lymphoma. 1 Transformation into a more malignant phenotype is thought to be driven by viral infection, such as with Epstein-Barr virus or herpes simplex virus, as was cultured from wound swabs in this case. 2 Richter syndrome affects 1 in 10 patients with CLL and is treatable, but it has a poor prognosis, median survival being 10 months from diagnosis. 3 It presents with lymphadenopathy, hepatosplenomegaly, and raised serum lactate dehydrogenase levels. 3 Extranodal manifestations can occur, with ocular, renal, and neurological systems affected. 4 Once suspected, Richter syndrome (ie, background of CLL, worsening symptoms, and evidence of viral infection) is diagnosed by demonstrating CLL s histopathological phenotypic change through biopsy of the affected lymph, bone marrow, or as in this case, cutaneous involvement. 5 Managed first by hematology, our patient presented with a small pedunculated pink lesion on the lower left eyelid with spreading erythema. Over a 3-month period, small areas of developing eyelid necrosis (Fig 1) were treated for suspected fungal, viral, and bacterial infections. Despite the background of CLL and being positive for herpes simplex virus, without an early biopsy, the basin of eyelid CLL and its transformation to a higher grade of lymphoma were missed. The patient was referred to plastic surgery for assessment of potential NF. In a patient with CLL and cutaneous necrosis of the orbit, additional to the more common fungal and infective causes, although NF is less common, as an aggressive potentially deadly soft-tissue/fascial infection, it should be considered and either ruled out or treated. 6 The necrosis associated with NF (Fig 2) is, on examination, difficult to distinguish from that of Richter syndrome (Fig 1). Clinically, suspicion of both NF and Richter syndrome would be raised by clinical deterioration, but NF is expected to have a more acute (hours as opposed to days) time frame. The blistering, necrosis, and potential cutaneous thrombosis observed would not tend to demarcate into the more stable pattern, as seen with Richter syndrome, where the area affected corresponds to the basin of cutaneous CLL as opposed to progressive soft-tissue/fascial infection. The distinguishing factors included the more indolent course of Richter syndrome, as compared with NF, a failure to respond to antifungal/viral/bacterial therapies, and the need for an early biopsy. Conversely, on the basis of reviews of periorbital NF, using the rate of necrotic progression, or whether lesions demarcate, may not be a wholly reliable way to distinguish it from Richter syndrome. Luksich et al 7 somewhat controversially report that ocular NF presents less aggressively than in the rest of the body and may be treated conservatively. Given such presentations, the diagnostic suspicion of NF in this case is more understandable, but actually confounds the choice not to biopsy, prior to debridement. This error was made because of a lack of awareness of Richter syndrome and communication between the hematology and surgical specialties. Not only is Richter syndrome frequently a difficult diagnosis to establish but it also presents a therapeutic challenge. Treatment of Richter syndrome is primarily through the administration of monoclonal antibodies, chemotherapy, and steroids in the acute care setting. 8 Radiotherapy may be also be used in combination to control pain, lymphadenopathy, and neurological/spinal cord manifestations. Standard chemotherapies used in CLL are not effective, and most clinicians rely on combined CHOP-R therapy for diffuse large B-cell lymphoma: cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab. 8 With complete remission difficult to achieve, the use of allogeneic stem-cell transplantation has

shown early promise but is still in its infancy. The choice of the plastic surgery team to debride down to orbicularis was likely to have only added insult to an already immunocompromised patient, where prompt institution of steroids, targeted monoclonal antibodies, and chemotherapy would have given the patient the best outcome. REFERENCES 1. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391-401. 2. Dolcetti R, Carbone A. Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor? Infect Agent Cancer. 2010;5:22. 3. Jain P, O Brien S. Richter s transformation in chronic lymphocytic leukemia. Oncology (Williston Park). 2012;26(12):1146-52. 4. Kluk J, Moonim M, Duran A, et al. Cutaneous Richter syndrome: a better place to transform? Br J Dermatol. 2015;172(2):513-21. 5. Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood. 2014;123(11):1647-57. 6. Chaudhry AA, Baker KS, Gould ES, Gupta R. Necrotizing fasciitis and its mimics: what radiologists need to know. Am J Roentgenol. 2015;204(1):128-39. 7. Luksich JA, Holds JB, Hartstein ME. Conservative management of necrotizing fasciitis of the eyelids. Ophthalmology. 2002;109(11):2118-22. 8. Cwynarski K, van Biezen A, de Wreede L, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter s syndrome): a retrospective analysis from the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30:2211-7. Gorman, Ruston and Vennam. Periorbital Richter Syndrome. www.eplasty.com, Interesting Case, June 1, 2015